Research programme: Neurological disorders therapeutics - Asceneuron

Drug Profile

Research programme: Neurological disorders therapeutics - Asceneuron

Latest Information Update: 03 Nov 2016

Price : $50

At a glance

  • Originator Merck Serono
  • Developer Asceneuron
  • Class Small molecules
  • Mechanism of Action Amyloid beta-protein inhibitors; Hexosaminidase C inhibitors; Tau protein inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

  • New Molecular Entity Yes

Highest Development Phases

  • Preclinical Alzheimer's disease; Progressive supranuclear palsy

Most Recent Events

  • 06 Oct 2016 Preclinical development is ongoing for Alzheimer's disease in Switzerland
  • 06 Oct 2016 Preclinical trials in Progressive supranuclear palsy in Switzerland (unspecified route)
  • 02 Oct 2012 Preclinical trials in Alzheimer's disease in Switzerland (unspecified route)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at so we can help.

Back to top